688336.SHG Sunshine Guojian Pharmaceutical Shanghai Co Ltd
- Market cap
- CNY 30.6B
- P/E
- 9.9x
- P/B
- 3.19x
- ROE
- 9.0%
- Dividend yield
- 0.25%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 688336.SHG undervalued?
Graham number688336.SHG trades 18.7% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Sunshine Guojian Pharmaceutical Shanghai Co Ltd fundamental analysis
No fundamental analysis for Sunshine Guojian Pharmaceutical Shanghai Co Ltd yet.
Sunshine Guojian Pharmaceutical Shanghai Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Sunshine Guojian Pharmaceutical Shanghai Co Ltd
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of antibody drugs. Its products include Enbrel, a recombinant human type II tumor necrosis factor receptor-antibody fusion protein for the treatment of autoimmune rheumatism and immunology; Jiannipa, a recombinant anti-CD25 humanized monoclonal antibody injection to prevent acute rejection caused by kidney transplantation; and Enbrel…
Full company profileSunshine Guojian Pharmaceutical Shanghai Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Sunshine Guojian Pharmaceutical Shanghai Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 961M | 1.10B | 1.14B | 1.18B | 655M | 929M | 825M | 1.01B | 1.19B | 4.20B | 1.86B |
| Gross Profit | 893M | 999M | 1.02B | 1.03B | 553M | 719M | 621M | 791M | 889M | 4.20B | 1.51B |
| Operating Income | 263M | 441M | 421M | 260M | -203M | -43.6M | 36.9M | 318M | 727M | 3.29B | 745M |
| EBITDA | 385M | 516M | 532M | 361M | -146M | 82.2M | 153M | 408M | 836M | 3.41B | 830M |
| Net Income | 268M | 389M | 370M | 229M | -217M | 18.1M | 49.3M | 295M | 705M | 2.94B | 783M |
| EPS | 0.53 | 0.76 | 0.72 | 0.43 | -0.37 | 0.03 | 0.08 | 0.48 | 1.14 | 4.76 | 0.87 |
| Balance Sheet | |||||||||||
| Total Assets | 2.89B | 3.34B | 3.70B | 3.32B | 4.95B | 4.89B | 5.10B | 5.31B | 5.97B | 8.96B | 9.03B |
| Total Liabilities | 340M | 427M | 427M | 416M | 433M | 350M | 499M | 426M | 428M | -5.86B | 401M |
| Shareholders' Equity | 2.46B | 2.85B | 3.22B | 2.87B | 4.50B | 4.54B | 4.61B | 4.90B | 5.57B | 5.86B | 8.68B |
| Cash & Short-term Investments | 356M | 339M | 202M | 1.14B | 2.71B | 2.37B | 2.58B | 1.88B | 1.37B | 1.72B | 197M |
| Total Debt | - | - | - | - | - | - | 150M | 50.0M | 50.0M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 354M | 235M | 361M | 588M | -40.1M | -244M | 233M | 416M | 281M | 3.04B | - |
| Capital Expenditure | 105M | 69.1M | 90.1M | 130M | 227M | 264M | 221M | 236M | 281M | 253M | 241M |
| Free Cash Flow | 250M | 166M | 271M | 457M | -267M | -508M | 12.2M | 181M | 354K | 2.79B | -276M |
| Ratios | |||||||||||
| ROE | 10.9% | 13.6% | 11.5% | 8.0% | -4.8% | 0.4% | 1.1% | 6.0% | 12.7% | 50.2% | 9.0% |
| ROA | 9.3% | 11.6% | 10.0% | 6.9% | -4.4% | 0.4% | 1.0% | 5.6% | 11.8% | 32.8% | 8.7% |
| Net Profit Margin | 27.9% | 35.2% | 32.4% | 19.5% | -33.2% | 1.9% | 6.0% | 29.1% | 59.0% | 70.0% | 42.2% |
| Debt to Equity | - | - | - | - | - | - | 0.03x | 0.01x | 0.01x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Sunshine Guojian Pharmaceutical Shanghai Co Ltd dividends
- Dividend yield
- 0.25%
- Forward dividend
- 0.47 CNY
- Payout ratio
- 2.6%
- Ex-dividend date
- Nov 6, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 76.5M | 0.12 | 2.6% |
| 2024 | CNY 51.2M | 0.08 | 7.3% |
| 2023 | CNY 1.47M | 0.00 | 0.5% |
| 2022 | CNY 1.22M | 0.00 | 2.5% |
| 2021 | CNY 1.22M | 0.00 | 6.8% |
| 2020 | CNY 1.22M | 0.00 | - |
| 2019 | CNY 716M | 1.34 | 312.5% |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.45:1 on Jun 18, 2026.
Who owns Sunshine Guojian Pharmaceutical Shanghai Co Ltd
- Insiders 84.44%
- Institutions 5.38%
- Public & others 10.18%
- Shares outstanding 896M
- Free float 139M
Sunshine Guojian Pharmaceutical Shanghai Co Ltd company profile
- Company name
- Sunshine Guojian Pharmaceutical Shanghai Co Ltd
- Ticker
- 688336.SHG
- ISIN
- CNE1000062X2
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,012
- Fiscal year end
- December
- Address
- No. 399, Libing Road, Shanghai, China, 201203
- Phone
- 86 21 8029 7676
- Website
- 3s-guojian.com
About Sunshine Guojian Pharmaceutical Shanghai Co Ltd
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of antibody drugs. Its products include Enbrel, a recombinant human type II tumor necrosis factor receptor-antibody fusion protein for the treatment of autoimmune rheumatism and immunology; Jiannipa, a recombinant anti-CD25 humanized monoclonal antibody injection to prevent acute rejection caused by kidney transplantation; and Enbrel, an anti-IL-17A humanized monoclonal antibody ambroxol injection for the treatment of moderate to severe plaque psoriasis. The company was founded in 2002 and is based in Shanghai, China.
Sunshine Guojian Pharmaceutical Shanghai Co Ltd management
4- Ms. Yanli LiuGM & Director · born 1981
- Ms. Hongmei NiuChief Financial Officer · born 1990
- Mr. Qi ZhangSecretary of Board of Directors · born 1984
- Lirong ZhengAccounting Supervisor